Tumor Regression Grade As Predictor of Adjuvant Therapy

Recruiting now

Conditions studied: Esophageal Squamous Cell Carcinoma (ESCC)

In brief

Neoadjuvant therapy followed by surgery is preferred for locally advanced esophageal squamous cell carcinoma, but the necessity of adjuvant therapy remains controversial. Tumor regression grade reflects the response to neoadjuvant therapy and may predict patient prognosis, yet its role in guiding adjuvant therapy remains unexplored.

Key facts

Study ID

NCT06710665

Run by

Fujian Medical University Union Hospital

People needed

400

Starts

2024-10-01

Expected to finish

2025-10-10

Last updated by the study team

2024-11-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• (I) underwent R0 resection with either two-field or three-field lymphadenectomy (II) received neoadjuvant therapy such as preoperative radiotherapy, chemoradiotherapy, or combined immunotherapy (III) had esophageal squamous cell carcinoma pathology.

You may not qualify if…

• (I) Patients with incomplete clinical data or follow-up information (II) Diagnosed with multiple primary malignancies

Where it is running

• Fujian Medical University Union Hospital — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.